Genetesis
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Genetesis sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).
Genetesis: 9 sponsored US clinical trials, 1 recruiting.
Genetesis sponsors 9 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 7 completed. The most-studied condition in this pipeline is Coronary; Ischemic, with 1 trials.
Top-decile sponsor footprint
Genetesis ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
9 total, page 1 of 1
A Registry of Cardiac PET and CardioFlux Magnetocardiography in Patients With Suspected Coronary Ischemia.
NCT05868902
MCG as a Noninvasive Diagnostic Strategy for Suspected INOCA (MICRO2)
NCT06212466
MCG for Suspected INOCA Confirmed by Thermodilution-Derived CFR
NCT06139094
MCG as a Noninvasive Diagnostic Strategy for Suspected Coronary Microvascular Dysfunction
NCT05150054
Acute Coronary Syndrome CardioFlux TM Study (ACCMED)
NCT04739267
Women's Assessed Cardiovascular Evaluation With MCG
NCT04739280
Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
NCT03968809
Use of Magnetocardiography in Evaluation of Patients Going for Cardiac Catheterization
NCT04044391
Magnetocardiography Using a Novel Analysis System (Cardioflux) in the Evaluation of Emergency Department Observation Unit Chest Pain Patients
NCT03255772
Therapeutic Areas
What is open in the Genetesis pipeline
1 recruiting of 9 indexed (11% open); 7 completed (78%).
Phase labels are sparse on this sponsor index, so phase mix is not charted here.
Top condition: Coronary; Ischemic (1 trial), 2 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Genetesis: open-pipeline peers nationwide
Peers matched on 9 registered trials and 11% open enrollment, not the therapeutic-area sidebar.
Genetesis sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 9 trials (± recruiting share)
- 4D Molecular Therapeutics · 9 trials · 44% recruiting
- 9 Meters Biopharma · 9 trials · 0% recruiting
- Aadi Bioscience · 9 trials · 33% recruiting
- Ablynx, a Sanofi company · 9 trials · 0% recruiting
Sponsors near 11% open enrollment (± trial volume)
- ADC Therapeutics S.A. · 11% recruiting · 18 trials
- Adrian Vella · 11% recruiting · 9 trials
- AIDS Malignancy Consortium · 11% recruiting · 45 trials
- Amylyx Pharmaceuticals · 11% recruiting · 9 trials
Related
What to do with this Genetesis page
9 registered trials is a research-attention snapshot, not an endorsement of Genetesis or any single study.
- 1 of Genetesis's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Coronary; Ischemic is the condition Genetesis studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Coronary; Ischemic trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Genetesis pipeline card: 9 registered trials from official public datasets.Report a data error.